Funded Startups in Bridgewater
Recent funding activity tied to Bridgewater spans from 2022-08-10 (Pier Augé, Corporate Round, undisclosed) through 2025-12-11 (Cayuga Biotech, Seed, $5M).
Recent funding activity tied to Bridgewater spans from 2022-08-10 (Pier Augé, Corporate Round, undisclosed) through 2025-12-11 (Cayuga Biotech, Seed, $5M). In the disclosed amounts, one round stands far above the rest: Insmed’s Post-IPO Debt on 2022-10-19 at $500M, while the next-largest disclosed entry is Juniper Biosciences’ $40M (2025-12-01). That magnitude gap makes Insmed an outlier within this set.
Sectors cluster around life sciences and healthcare: Biotechnology appears in Cayuga Biotech (2025-12-11, $5M), Insmed (2022-10-19, $500M), and again via the life-science framing of these entries, while Pharmaceutical Manufacturing (Juniper Biosciences, 2025-12-01, $40M) reinforces the biomedical mix. Stage information is also concentrated in early rounds for newer deals: two of the newest entries are labeled Seed (Cayuga Biotech on 2025-12-11 at $5M; Juniper Biosciences on 2025-12-01 at $40M), followed by smaller disclosed transactions like GoMeat Services’ $250K (2023-09-06).
Most recent rounds
6 shownRelated listings
Frequently asked
Which disclosed round is the clear outlier in this Bridgewater list, and how does it compare to the rest?
Insmed’s Post-IPO Debt on 2022-10-19 is disclosed at $500M, dwarfing the next-largest disclosed amount in the table: Juniper Biosciences’ $40M on 2025-12-01. The remaining disclosed figures sit far below $40M (e.g., $5M for Cayuga Biotech on 2025-12-11 and $500K for Insmed’s same row is the peak).
Are there any obvious date clusters among the most recent Bridgewater rounds shown here?
Yes. Two Seed rounds closed within a tight window in December 2025: Juniper Biosciences on 2025-12-01 ($40M) and Cayuga Biotech on 2025-12-11 ($5M). Outside that, disclosed Bridgewater-linked rounds appear more sparsely across 2023 and 2022 (e.g., GoMeat Services on 2023-09-06 at $250K; Insmed on 2022-10-19 at $500M).
How much of the list is dominated by life-science sectors versus other categories?
Biotechnology appears in multiple entries (Cayuga Biotech, Seed, 2025-12-11 at $5M; Insmed, Post-IPO Debt, 2022-10-19 at $500M), and Pharmaceutical Manufacturing appears as well via Juniper Biosciences (Seed, 2025-12-01 at $40M). Non–life-science categories in the visible rows include Commerce and Shopping (GoMeat Services, 2023-09-06 at $250K), Artificial Intelligence (Kim Technologies, 2023-04-06, undisclosed), and Consumer Goods (Pier Augé, 2022-08-10, undisclosed).
What stage mix shows up most often in the six most recent rows?
Seed is the most visible stage label in the set, appearing twice at the top of the list: Juniper Biosciences (Seed, 2025-12-01, $40M) and Cayuga Biotech (Seed, 2025-12-11, $5M). Other labeled stages are single occurrences (GoMeat Services: Series Unknown; Insmed: Post-IPO Debt; Pier Augé: Corporate Round), with two rows also carrying undisclosed amounts.
Which entries are undisclosed versus disclosed, and does that create a coverage gap around the top of the list?
In the six rows shown, four amounts are disclosed ($5M, $40M, $250K, $500M) and two are undisclosed (Kim Technologies on 2023-04-06; Pier Augé on 2022-08-10). Notably, both undisclosed entries are not among the newest two deals; the most recent entries are disclosed (Cayuga Biotech at $5M and Juniper Biosciences at $40M in December 2025).
Which entries are geographically outside “Bridgewater, New Jersey,” and what does that imply for interpreting the list?
One entry is outside Bridgewater, New Jersey: Pier Augé is listed as Bridgewater, Somerset, United Kingdom (Corporate Round, 2022-08-10) and has an undisclosed amount. The remaining visible companies are listed in Bridgewater, New Jersey, United States, including Insmed ($500M on 2022-10-19) and Juniper Biosciences ($40M on 2025-12-01).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.